Another issue with ABT's multi drug combo is how to treat failures.
A nuke based combo appears to need another class of drug (outside of ribavirin) to be effective in GT1 patients. Could patients failing to achieve a SVR using ABT's combo develop resistance to one or more partnering classes thus reduce their chances of achieving a SVR under second-line nuke-based or interferon-based therapy?
If a treatment-naive patient fails a nuke/NS5A combo it's safe to say they can be retreated in the future with a nuke/P.I. without concerns over class resistance.
Market Data 
Markets 
AI
